PRASCEND is the first and only medicine available in the US that is approved by the FDA to treat pituitary pars intermedia dysfunction (PPID), historically termed equine Cushing’s disease, in horses. As part of the FDA approval process. PRASCEND was rigorously tested to prove its safety and effectiveness in reducing signs of PPID in horses.
Pituitary Pars Intermedia Dysfunction is one of the most common diseases of the endocrine system that can affect horses and ponies. PPID causes the horse’s pituitary gland, which utilizes hormones to control body functions, to work overtime.
PRASCEND is for use in horses only. Treatment with PRASCEND has been observed to cause inappetence, with most cases being transient. Weight loss, lethargy and behavioral changes may be observed in some horses. If severe, a temporary reduction of dose may be necessary. PRASCEND has not been evaluated in breeding, pregnant or lactating horses. As PRASCEND is a dopamine agonist, it may interfere with reproductive hormones involved in these groups of horses. The concurrent use of dopamine antagonists should be avoided since these agents may diminish the effectiveness of PRASCEND. PRASCEND should not be used in horse with hypersensitivity to pergolide meylate or other ergot derivatives. Refer to the package insert for complete product information.
Human Safety Warning
In case of accidental ingestion of PRASCEND, seek medical advice immediately and show the package leaflet or the label to the physician. Do not induce vomiting. People with known hypersensitivity to pergolide or other ergot derivatives should avoid contact with the veterinary medicinal product and should not administer it. Keep out of the reach of children. Pregnant or lactating women should wear gloves when administering the product.
Storage: Store at or below 25°C (77 F)
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
To be administered orally, once daily, by dissolving the tablet with a small amount of water and/or mixing with molasses or feed. Tablets dissolved in water can be administered with a syringe or mixed with feed. Administer the dissolved product immediately. To minimize the risk of human exposure, tablets should not be crushed.
Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily.